Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of the Me Mini Device for Hair Removal

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy males and females, between 18 and 65 years of age.~2. Subject has Black or dark brown terminal hairs in the areas to be treated.~3. Terminal hair density requirement of greater than 15 hairs within the hair count site (3x3 cm area) as determined by manual hair count performed by the study investigator.~4. Willing to sign informed consent.~5. Willing to follow the treatment schedule and post treatment follow-up.~6. Willingness to have photographs of the treated area taken that may be used for marketing and educational presentation and/or publications and willing to sign the photo-release form.~7. Willingness to avoid excessive sun exposure two weeks prior to treatments~Exclusion Criteria:~Skin and Hair~1. Subjects with white, red, light brown and/ or blonde hairs in the areas to be treated.~2. A history of keloidal scarring (hypertrophic scars or keloids).~3. Active dermatologic lesion or infection in the treatment site.~4. Subject has permanent tattoos or makeup in the treatment area.~5. Recently tanned in the area to be treated and/or unable or unlikely to refrain from tanning during the study.~6. Subject has disease related to photosensitivity, such as porphyria, polymorphic light eruption, solar urticaria, lupus, etc~7. Subject has a history of herpes outbreak in the area of treatment, unless receiving preventative treatment from physician Other Medical Conditions~8. Pregnant, planning to become pregnant, hormone fluctuations and/or breast feeding during the experiment.~9. Subjects with Diabetes (Type I or II) or other systemic or metabolic condition~10. Subject has an active electrical implant anywhere in the body, such as a pacemaker, an internal defibrillator, insulin pump, incontinence device, etc.~11. Subject suffers from epilepsy.~12. Subject has active cancer, or has a history of skin cancer or any other cancer in the area to be treated, including presence of malignant or pre-malignant pigmented lesions.~13. Subject received radiation therapy or chemotherapy treatments with the past 3 months.~14. Subject has known anticoagulative or thromboembolic condition or is on any form of anticoagulation treatment.~15. Subject has a history of immunosuppressant/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.~16. Subject has any other condition which in the physician's opinion would make it unsafe for the subject to be treated.~    Medication/treatments~17. Subject had rotating type tweezer epilator treatment, or waxing within the last 3 months~18. Subject had electrolysis treatment within the last 6 months over the treatment area.~19. Subject had any type of professional intense pulsed light (IPL), laser or RF hair removal in the treatment site within the last 6 months.~20. Subject is taking medication known to induce photosensitivity, including non-steroidal anti-inflammatory agents, tetracyclines, phenothiazines, thiazide diuretics, sulfonylureas, sulfonamides, Dacarbazine(DTIC), fluorouracil, vinblastine, and griseofulvin within 4 weeks of therapy.~21. Subject has been taking Accutane® within 6 months of therapy.~22. Subject has been on steroid regimen during the last three months.~23. Subject is on Gold therapy (for arthritis treatment).~24. Subjects who have participated in any clinical study within the 30 days prior to the first planned treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Me mini (Type: EXPERIMENTAL): Subjects treated with Me mini device

Based on this trial design, predict the completion outcome and termination type (if applicable).